Bicycle Therapeutics plc (BCYC)
NASDAQ: BCYC · Real-Time Price · USD
3.620
-0.040 (-1.09%)
At close: Nov 2, 2026, 4:00 PM EST
3.600
-0.020 (-0.55%)
After-hours: Nov 2, 2026, 7:30 PM EST

Bicycle Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
83.5372.5935.2826.9814.4611.7
Revenue Growth
194.75%105.77%30.76%86.52%23.65%12.58%
Gross Profit
-80.53-156.5-129.59-120.68-67.15-33.18
Operating Income
-154.03-242.87-208.77-189.95-116.65-65.62
Net Income
-141.79-218.96-169.03-180.66-112.72-66.82
Earnings Per Share
-2.03-3.16-2.90-5.08-3.80-2.67
EPS Growth
------

Cash & Debt

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
469.93628.11879.52526.42339.15438.68
Total Debt
14.1816.859.4944.9644.3344.34
Net Cash (Debt)
455.74611.26870.03481.47294.83394.34
Net Cash Growth
-29.08%-29.74%80.70%63.30%-25.24%228.03%
Net Cash Per Share
6.548.8214.9513.539.9415.73

Cash Flow & CapEx

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
-175.18-249.68-164.72-60.63-86.11-14.79
Capital Expenditures
-1.86-2.35-1.24-2.93-18.99-2.03
Free Cash Flow
-177.04-252.03-165.96-63.56-105.1-16.82
Free Cash Flow Growth
------

Margins

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingSep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
-96.41%-215.60%----283.69%
Operating Margin
-184.40%-334.59%-591.84%-704.13%-806.56%-560.98%
Pretax Margin
-166.52%-301.45%-492.69%-664.32%-789.88%-585.47%
Profit Margin
-169.75%-301.66%-479.18%-669.72%-779.35%-571.25%
FCF Margin
-211.95%-347.21%-470.47%-235.61%-726.67%-143.83%

Valuation

Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingNov '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
PS Ratio
3.046.7727.4028.4360.76152.99